A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse

The purpose of this investigator-initiated phase II trial was to assess the efficacy of Elo-KRd quadruplet therapy in patients with MM in first relapse. Although the accrual target was not met, our results suggest efficacy and tolerability of this combination in lenalidomide-refractory population enriched for high-risk. Longitudinal immunophenotyping revealed a T cell signature correlating with response.

Source: Clinical Lymphoma, Myeloma and Leukemia - April 6, 2023 Category: Hematology Authors: Manisha Bhutani, David M. Foureau, Myra Robinson, Fei Guo, Kateryna Fesenkova, Shebli Atrash, Barry Paul, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, Katherine Rigby, James T. Symanowski, Sarah Norek, Mallory R. Tucker, Lawrence J. Druhan, Peter M. V Tags: Original Study Source Type: research